A new multiplexed SARS-CoV-2 serological assay using advanced flow cytometry
21 Jun 2022
Antibodies directed against the receptor binding domain (RBD) of the SARS-CoV-2 spike protein demonstrate potent neutralizing activity. Several classes of these antibodies have been identified in COVID-19 patients, and are largely responsible for the protective immunity induced by the current COVID-19 vaccines. Thus, there is an ongoing need to accurately determine the quantity and duration of the antibody response against the SARS-CoV-2 Spike RBD.
Combined detection of three isotypes (IgG, IgM and IgA) of anti-SARS-CoV-2 Spike RBD antibodies in a single well of a 96- or 384-well plate not only saves time and precious patient samples, but also provides a dynamic and comprehensive profile of the humoral response over time, following natural infection with SARS-CoV-2 or immunization with COVID-19 vaccines.
This webinar introduces the newly developed, validated kit, which provides a rapid, robust and sensitive serological assay for the simultaneous measurement of IgG, IgM, and IgA anti-SARS-CoV-2 Spike RBD antibodies in a single sample of human serum or plasma, with detection levels in the pg/mL range.
Key learning objectives
- Discussion on the value of assessing levels of the three major isotypes of anti-SARS-CoV-2 Spike RBD antibodies to characterize the type and kinetics of the antibody response to COVID-19 infection or vaccination.
- Details of how the SARS-CoV-2 (IgG, IgM and IgA) kit and advanced flow cytometry instrumentation are able to perform a multiplexed assessment of the three major isotypes of SARS-CoV-2 Spike RBD antibodies.
Who should attend?
- Immunologists, virologists, and drug discovery researchers within hospitals, clinics, contract testing laboratories, biotechnology, pharmaceuticals, biopharma, and academia.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.